2,103,745 Shares in BrainsWay Ltd. (NASDAQ:BWAY) Bought by Valor Management LLC

Valor Management LLC purchased a new position in shares of BrainsWay Ltd. (NASDAQ:BWAY - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 2,103,745 shares of the company's stock, valued at approximately $19,838,000. BrainsWay makes up approximately 8.0% of Valor Management LLC's portfolio, making the stock its 2nd largest position. Valor Management LLC owned approximately 11.18% of BrainsWay at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Two Sigma Investments LP raised its position in shares of BrainsWay by 2.0% in the 4th quarter. Two Sigma Investments LP now owns 92,755 shares of the company's stock valued at $875,000 after purchasing an additional 1,786 shares in the last quarter. Rhumbline Advisers raised its position in shares of BrainsWay by 10.8% in the 4th quarter. Rhumbline Advisers now owns 21,966 shares of the company's stock valued at $207,000 after purchasing an additional 2,144 shares in the last quarter. Cubist Systematic Strategies LLC raised its position in shares of BrainsWay by 14.6% in the 4th quarter. Cubist Systematic Strategies LLC now owns 19,228 shares of the company's stock valued at $181,000 after purchasing an additional 2,446 shares in the last quarter. Lazard Asset Management LLC acquired a new position in shares of BrainsWay in the 4th quarter valued at approximately $44,000. Finally, JPMorgan Chase & Co. raised its position in shares of BrainsWay by 61.9% in the 4th quarter. JPMorgan Chase & Co. now owns 23,918 shares of the company's stock valued at $226,000 after purchasing an additional 9,149 shares in the last quarter. 30.11% of the stock is owned by institutional investors and hedge funds.

BrainsWay Stock Up 2.9%

Shares of BWAY traded up $0.30 during trading on Friday, reaching $10.73. The company's stock had a trading volume of 14,400 shares, compared to its average volume of 70,065. The company has a fifty day moving average of $9.17 and a two-hundred day moving average of $9.72. BrainsWay Ltd. has a twelve month low of $5.25 and a twelve month high of $11.79. The company has a market cap of $202.50 million, a price-to-earnings ratio of 107.31 and a beta of 1.25.

BrainsWay (NASDAQ:BWAY - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.02. The business had revenue of $11.54 million for the quarter, compared to analyst estimates of $11.45 million. BrainsWay had a return on equity of 3.52% and a net margin of 3.88%. As a group, equities analysts forecast that BrainsWay Ltd. will post 0.08 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $16.00 target price on shares of BrainsWay in a research report on Wednesday, March 12th.

About BrainsWay

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.